Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
News about bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) centers on its work in noninvasive lung cancer diagnostics and related lung disease research. The company’s disclosures describe CyPath® Lung, a sputum-based test that uses advanced flow cytometry and artificial intelligence (AI) to detect cell populations indicative of malignancy. Clinical data reported by bioAffinity show high sensitivity, specificity and accuracy for detecting lung cancer in high-risk patients with small lung nodules, including cases identified at Stage 1A.
Readers following BIAFW news will see updates on clinical and real-world case studies where CyPath® Lung contributed to early diagnosis or helped avoid unnecessary invasive procedures. Company announcements also highlight presentations at professional meetings, such as pulmonary and cancer-focused conferences, where research on CyPath® Lung’s processing methods, sample handling and diagnostic performance is shared with clinicians and researchers.
Another key news theme is laboratory quality and accreditation. bioAffinity reports that its subsidiary Precision Pathology Laboratory Services (PPLS) maintains College of American Pathologists (CAP) accreditation and CLIA certification, which the company associates with quality, accuracy and patient safety across its diagnostic services, including CyPath® Lung.
Investors and healthcare professionals can also expect news on intellectual property developments, such as U.S. and international patents covering the AI-built diagnostic algorithm and the broader flow cytometry platform for assessing lung health and multiple lung diseases. In addition, corporate and financial news items describe equity financings, warrant-related transactions, and commentary from management linking revenue trends and operating decisions to the commercialization of CyPath® Lung.
For those tracking BIAFW, the news flow provides context on how bioAffinity is advancing its noninvasive diagnostic platform, expanding clinical use of CyPath® Lung, and managing its capital structure and Nasdaq listing status.
bioAffinity Technologies (NASDAQ: BIAF) has announced significant efficiency improvements to its CyPath® Lung cancer detection test. The company has achieved a 50% reduction in data acquisition time and a 60% decrease in sample processing costs. These optimizations are expected to deliver a 10% increase in overall throughput and a 25% decrease in unit cost.
The CyPath® Lung test, which uses flow cytometry and artificial intelligence to detect lung cancer in sputum samples, has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules. A recent economic impact study showed potential cost savings of $2,773 per Medicare patient and $6,460 per privately insured patient if CyPath® Lung is added to the standard of care, potentially saving $379 million and $895 million respectively nationwide.
bioAffinity Technologies (BIAF) reported significant financial results for 2024, with revenue surging 270% to $9.4 million from $2.5 million in 2023. The company's flagship product, CyPath® Lung, saw orders grow by approximately 1,400% over 2023, driven by increased physician adoption and expanded insurance coverage including Medicare reimbursement.
Key achievements include the addition of CyPath® Lung to the U.S. Federal Supply Schedule, providing access to 1,380 government healthcare facilities. The company expanded its physician network by over 300% in 2024. However, for 2025, BIAF projects lower revenue of $6-8 million due to discontinuing unprofitable pathology services.
Financial results show operating expenses of $18.3 million and a net loss of $9.0 million ($0.75 per share) for 2024. Cash position stood at $1.1 million as of December 31, 2024, with an additional $1.4 million raised through warrant exercises in February 2025.
bioAffinity Technologies (BIAF) released a case study highlighting how their CyPath® Lung test successfully detected a second primary lung cancer in a high-risk patient. The 72-year-old patient, with a 50 pack-year smoking history, had previously undergone surgery for stage 1A non-small cell lung cancer in 2023.
The test's positive result led to further investigation, revealing small cell carcinoma distinct from the initial cancer. Dr. Gordon H. Downie, Director of the Pulmonary Nodule Clinic at Titus Regional Medical Center, emphasized the test's value in real-time detection of malignant cells.
A recent study in the Journal of Health Economics Outcomes and Research demonstrated potential cost savings with CyPath® Lung:
- Medicare patients: Average savings of $2,773 per patient ($379 million total)
- Private-payer patients: Average savings of $6,460 per patient ($895 million total)
bioAffinity Technologies (NASDAQ: BIAF) released a case study demonstrating how their CyPath® Lung test successfully identified a breast cancer recurrence in an 80-year-old high-risk patient. The test's real-time assessment of lung microenvironment led to the discovery when evaluating indeterminate lung nodules.
The patient, a former smoker with COPD and previous breast cancer history, underwent the test after a CT scan detected an eight-millimeter non-calcified nodule. The CyPath® Lung test's positive result prompted further investigation, leading to a mammogram that confirmed new breast cancer.
A recent study in the Journal of Health Economics Outcomes and Research indicated significant potential cost savings: $2,773 per Medicare patient and $6,460 per private-payer patient if CyPath® Lung were included in standard care. This could amount to total savings of $379 million for Medicare and $895 million for private insurance patients based on 2022 screening numbers.
bioAffinity Technologies (NASDAQ: BIAF) has released physician case studies demonstrating the effectiveness of their CyPath® Lung noninvasive lung cancer detection test. A notable case study presented by Dr. Gordon H. Downie showed how the test helped avoid unnecessary invasive procedures for an 85-year-old high-risk patient.
The test's 'Unlikely Lung Cancer' result prevented risky biopsies, leading to a successful 'watchful waiting' approach where the patient's nodules resolved within three months. Dr. Downie, Director of the Pulmonary Nodule Clinic at Titus Regional Medical Center, has incorporated CyPath® Lung into his protocol for patients with indeterminate nodules.
A peer-reviewed economic impact study published in the Journal of Health Economics Outcomes and Research revealed significant potential cost savings: $2,773 per Medicare patient (total $379 million) and $6,460 per private-payer patient (total $895 million) if implemented as standard care for positive lung cancer screenings in 2022.
bioAffinity Technologies (NASDAQ: BIAF) has announced strategic cost-cutting measures expected to save approximately $4 million annually at its subsidiary Precision Pathology Laboratory Services (PPLS). The company is implementing:
- 38% workforce reduction in non-CyPath® Lung personnel at PPLS
- Operational efficiency improvements
- Discontinuation of low-margin pathology services
The restructuring aims to accelerate commercial growth of CyPath® Lung, their noninvasive early-stage lung cancer detection test. While these actions will decrease revenue, they are expected to improve PPLS's profitability by focusing on CyPath® Lung and high-value service lines. The company plans to launch a focused government marketing program next quarter, targeting Veterans Administration and Department of Defense medical centers, following CyPath® Lung's availability through the Federal Supply Schedule.
bioAffinity Technologies (NASDAQ: BIAF) has completed a warrant inducement transaction, raising $1.4 million in gross proceeds. The deal involved four existing accredited investors exercising warrants to purchase 2,438,473 shares of common stock. The company reduced the exercise price of existing warrants from $1.50 to $0.58 per share.
As part of the agreement, investors received new unregistered warrants to purchase up to 2,926,166 shares (120% of exercised shares) with an exercise price of $0.85 per share. These new warrants will become exercisable upon stockholder approval and expire five years after approval. WallachBeth Capital served as the sole placement agent for the transaction.
bioAffinity Technologies (NASDAQ: BIAF) has closed warrant exercise agreements with four accredited investors, generating gross proceeds of $1.4 million. The transaction involves the exercise of existing warrants to purchase 2,438,473 common shares at a reduced exercise price of $0.58 per share (down from $1.50).
In exchange, investors will receive new unregistered warrants to purchase up to 2,926,166 shares (120% of exercised shares) at $0.85 per share. These new warrants will become exercisable upon stockholder approval and expire five years after approval. WallachBeth Capital serves as the sole placement agent for this warrant inducement transaction.
bioAffinity Technologies (NASDAQ: BIAF) has secured approximately $1.4 million in gross proceeds through warrant exercise agreements with three existing accredited investors. The investors will exercise warrants to purchase 2,438,473 common shares at a reduced price of $0.58 per share, down from the original $1.50.
As part of the agreement, investors will receive new unregistered warrants to purchase up to 2,926,168 shares (120% of exercised shares) at $0.85 per share. These new warrants will become exercisable upon stockholder approval and expire five years after approval. The transaction, managed by WallachBeth Capital as sole placement agent, is expected to close on February 26, 2025.
bioAffinity Technologies (NASDAQ: BIAF) has secured warrant exercise agreements with three existing accredited investors, generating $1.4 million in gross proceeds. The agreement involves the exercise of existing warrants for 2,438,473 common stock shares at a reduced price of $0.58 per share (down from $1.50).
In exchange, investors will receive new unregistered warrants to purchase 2,926,168 shares (120% of exercised shares) at $0.85 per share. These new warrants will become exercisable upon stockholder approval and expire five years after approval. The transaction, with WallachBeth Capital as sole placement agent, is expected to close around February 26, 2025.